To provide the information your oncologist is not telling you or doesn't have the time to!
Three different problems seen in recent weeks— a steroid reflex, a test without a plan, a patient chasing a rumor — but the same underlying discipline: ask whether what you’re doing actually changes the outcome, and be honest when it doesn’t. As always, I welcome pushback and other perspectives — feel free to reach out. …
A melanoma oncologist unpacks the new Phase 3 personalized mRNA cancer vaccine data — what it shows, what’s still unknown, and the questions patients are asking this week.
After two rejections, the FDA approved a new melanoma therapy that finally reaches beyond the skin — into the liver, into the lungs. Here’s why the third try worked.
A mountainside peer-to-peer call, three organizations, and one melanoma patient who now has a shot at TIL therapy — a look at what happens when payers, manufacturers, and providers actually move together.
OBX-115 engineered TIL therapy achieved a 67% response rate in melanoma patients who failed immunotherapy — with no IL-2 and outpatient-friendly dosing.
Sometimes the most important advances are not breakthroughs in biology, but breakthroughs in giving patients one more meaningful option.
The BRAF Pathway to TIL Program transforms TIL therapy from a last-minute scramble into a proactive treatment strategy.
I wanted to begin this post with a brief update and a moment of gratitude. AdventHealth Orlando has now been activated as an Authorized TIL Treatment Center for Iovance’s lifileucel, also known as Amtagvi, for eligible patients with advanced melanoma. Reaching this milestone in roughly three months has been both meaningful and energizing, especially as …
When science stays the course, time becomes part of the treatment.
Emerging data from ESMO 2025 highlight encouraging activity of the oncolytic virus RP1 plus nivolumab across several advanced non‑melanoma skin cancers, especially in PD‑1 naive and refractory settings.